Presentation is loading. Please wait.

Presentation is loading. Please wait.

Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro.

Similar presentations


Presentation on theme: "Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro."— Presentation transcript:

1 Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro Okami, MD, Toshiteru Tokunaga, MD, Fumio Imamura, MD, Tomio Nakayama, MD, Atsuo Inoue, MD, Keiko Kuriyama, MD  The Annals of Thoracic Surgery  Volume 101, Issue 2, Pages (February 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Algorithms for deciding on the type of resection based on the modern indication. (GGO = ground-glass opacity; LN = lymph node; VATS = video-assisted thoracic surgery.) (reprinted from Kodama K, et al, Eur J Cardiothorac Surg 2008;34: [4].) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Sample inclusion and exclusion criteria. (GGO = ground-glass opacity; NSCLC = non-small cell lung cancer.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Kaplan-Meier survival curves categorized as segmentectomy (red line) or lobectomy (black line). (A) Overall survival curves in the entire cohort, (B) local-regional relapse-free survival in the entire cohort, (C) overall survival curves in the propensity-matched group, and (D) local-regional recurrence-free survival in the propensity-matched group. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions


Download ppt "Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro."

Similar presentations


Ads by Google